Psoriasis drug to treat diabetes?

The US study, in which 49 patients with type 1 diabetes were randomised to receive alefacept, a drug targeting CD4 and CD8 cells, or placebo, showed that four-hour C-peptide area under the curve (AUC) increased with alefacept but declined with placebo after 12 months.

While the primary endpoint of a change in two-hour C-peptide AUC was not met, daily insulin use and hypoglycaemic events were greater in the placebo group compared to the alefacept group.

Lancet Diabetes and Endocrinology 2013; online 23 Sept